Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253077 | 0.91 | CASP3 (0.48) | CASP3MDM4TP53KMT2ASLC17A5 | |
| SCHEMBL10020438 | 0.90 | MDM4 (0.54) | CASP3MDM4TP53SLC17A5 | |
| SCHEMBL1739174 | 0.90 | MDM4 (0.54) | CASP3MDM4TP53SLC17A5 | |
| SCHEMBL27129147 | 0.89 | MDM4 (0.49) | CASP3MDM4TP53KMT2ASLC17A5 | |
| SCHEMBL27008576 | 0.89 | MDM4 (0.49) | CASP3MDM4TP53KMT2ASLC17A5 | |
| SCHEMBL1740641 | 0.86 | CASP3 (0.44) | CASP3MDM4TP53KMT2ASLC17A5 | |
| SCHEMBL31197005 | 0.84 | MDM4 (0.54) | CASP3MDM4TP53SLC17A5 | |
| SCHEMBL29445618 | 0.84 | CASP3 (0.53) | CASP3MDM4TP53KMT2A | |
| SCHEMBL12510996 | 0.84 | CASP3 (0.53) | CASP3MDM4TP53KMT2A | |
| SCHEMBL588375 | 0.83 | MDM4 (0.44) | CASP3MDM4TP53SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208480-A1 | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD J | 2005-09-22 | — | — | US | disclosed |
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD JESS (US) | 2004-01-15 | — | — | US | disclosed |
| US-6410775-B1 | HYDROPHILIC COUPLING | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-6207160-B1 | POLYPEPTIDES | LA JOLLA PHARMACEUTICAL COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-0954531-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | Lajolla Pharmaceutical Company (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0833648-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | JOLLA PHARMA (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| EP-0833648-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040197-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | CASP3 2653/4885MDM4 3152/4885TP53 1078/4885 |
| US-20050208480-A1 | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | CASP3 2653/4885MDM4 3152/4885TP53 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.